TriangleNCT00096278 · OUTCOME
Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of patients
- Interval / dispersion
- Not reported
- Time frame
- 5 years
What was measured
Percentage of patients who did not experience an event where events are defined as death from any cause.
Analysis population: Survival analysis was done 2 years after Disease Free Survival analysis. For Arm 2 one additional patient had follow up at the later analysis.
Groups in this outcome
Arm I (mFOLFOX6)
Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. oxaliplatin: Given IV leucovorin calcium: Given IV fluorouracil: Given IV
Arm II (Bevacizumab, mFOLFOX6)
Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity. oxaliplatin: Given IV leucovorin calcium: Given IV fluorouracil: Given IV bevacizumab: Given IV
| Group | Source count |
|---|---|
| Arm I (mFOLFOX6) | 1338 |
| Arm II (Bevacizumab, mFOLFOX6) | 1335 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm I (mFOLFOX6) | 77.6 | Not reported | Not reported | Not reported | Not reported |
| Arm II (Bevacizumab, mFOLFOX6) | 78.7 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 77.6
- group Id
- OG001
- value
- 78.7
- denoms
- counts
- group Id
- OG000
- value
- 1338
- group Id
- OG001
- value
- 1335
- units
- Participants
- description
- Percentage of patients who did not experience an event where events are defined as death from any cause.
- groups
- description
- Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. oxaliplatin: Given IV leucovorin calcium: Given IV fluorouracil: Given IV
- id
- OG000
- title
- Arm I (mFOLFOX6)
- description
- Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity. oxaliplatin: Given IV leucovorin calcium: Given IV fluorouracil: Given IV bevacizumab: Given IV
- id
- OG001
- title
- Arm II (Bevacizumab, mFOLFOX6)
- param Type
- NUMBER
- population Description
- Survival analysis was done 2 years after Disease Free Survival analysis. For Arm 2 one additional patient had follow up at the later analysis.
- reporting Status
- POSTED
- time Frame
- 5 years
- title
- Survival
- type
- SECONDARY
- unit Of Measure
- percentage of patients
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice